androgen deprivation therapy (ADT)

June 11, 2020June 11, 2020

Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds

News

Adding Xtandi (enzalutamide) to standard androgen deprivation therapy (ADT) significantly prolonged life by nearly a year for men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), final data from a Phase ... Read more

March 9, 2020March 9, 2020

Prolaris Test Predicts Which PC Patients Benefit from Combo Therapy, Study Finds

News

Myriad Genetics’ Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can identify which men with intermediate or high-risk prostate cancer will benefit from combining androgen ... Read more

March 4, 2020March 4, 2020

Genetic Test Seen to Predict Patients Helped by ADT Use After Surgery

News

A genetic test, called Decipher Prostate RP, can help to identify those prostate cancer patients with a relapse after surgery who will benefit most by adding androgen deprivation therapy (ADT) to radiation therapy, ... Read more

February 27, 2020February 27, 2020

Decipher GRID ‘Signature’ Predicts Chemo Benefits in HSPC, Research Shows

News

Decipher Bioscience’s proprietary artificial intelligence platform, Decipher GRID, one of the world’s largest urologic cancer genomic databases, can be used to identify subtypes of prostate cancer and predict which men ... Read more

February 11, 2020February 13, 2020

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

News

Treatment with Xtandi (enzalutamide) significantly extends the lives of men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), according to final data from a Phase 3 clinical trial. Developed by Pfizer and Astellas Pharma, Xtandi ... Read more

January 20, 2020

Zuclomiphene Safely Eases Hot Flashes Linked to ADT Use, Phase 2 Trial Reports

News

Interim Phase 2 trial results show that Veru‘s experimental treatment zuclomiphene citrate is well-tolerated and significantly reduces hot flashes in advanced prostate cancer patients using androgen deprivation therapy (ADT). These ... Read more

November 4, 2019

Veru Completes Enrollment for Zuclomiphene Citrate Trial for ADT-Induced Hot Flashes in PC

News

Veru Healthcare has completed patient enrollment for its Phase 2 clinical trial evaluating the use of zuclomiphene citrate (VERU-944) for the treatment of hot flashes in men receiving hormone therapy for ... Read more

July 24, 2019

Video Series Tackles Prostate Cancer and ADT Use in Doctor-Patient Format

News

CURE Media Group has introduced a video discussion series on topics of concern to prostate cancer patients, including cardiovascular risk management and androgen deprivation therapy (ADT). Called “ADT in Prostate Cancer: ... Read more

November 15, 2018

Radiation and Hormone Therapy Combo May Help Prevent Cancer’s Return After Prostatectomy

News

Prostate cancer patients who show signs of disease progression after surgery to remove the prostate may benefit by combining standard therapy with short-term androgen deprivation (STAD) and pelvic lymph node radiation therapy ... Read more

September 17, 2018

Androgen Deprivation Therapy Can Make Prostate Cancer More Aggressive, Study Finds

News

While androgen deprivation therapy (ADT) is an important treatment for prostate cancer, a new study has found that it sometimes promotes the transformation of prostate cancer cells into a more aggressive ... Read more